Procedures grew 17% last quarter and free cash flow nearly doubled to $2.5B in 2025 — yet ISRG trades a third below its January high, near a 52-week low, because the market is finally pricing one question: does a ~40× multiple survive the arrival of Medtronic and J&J? Four analyst lenses, three scenarios, four time horizons.
Gray line = ISRG’s actual price into today ($604 high Jan ’26 → $397 52-week low → $411.06 close); colored paths = synthesized scenario midpoints forward, probability-weighted (base 50% · bull 25% · bear 25%). Log-linear, mid-year marks. The reticle marks today. Wall Street 12-month consensus ≈ $575 (range $366–$750, “Buy/Strong Buy” from ~22 of 24 covering analysts, as of mid-June 2026).
Those probabilities are a judgment call — so make them yours. Drag to set how likely the bear and bull cases are (base takes the remainder); the blended target below, the dotted line on the chart, and the prob-weighted row of the scenario cards all update live.
The same fundamentals support very different conclusions depending on which framework you trust. Each lens below is a synthesized expert perspective with its own 12-month target.
A vastly underpenetrated market — ~9M line-of-sight procedures vs. 3.15M done in 2025 — with a razor-and-blade annuity still compounding ~17%. Da Vinci 5 is ramping fast (303 of 532 systems placed in Q4’25), cardiac clearance opened a ~160K-procedure TAM, and EBIT grew +40% in Q1. You pay up for the only proven platform.
With the manufacturing buildout finished, capex rolled off and free cash flow nearly doubled to $2.5B in 2025 — consensus models ~$4B in 2026. A fortress balance sheet (~$9.5B net cash, ~zero debt) and a completed buyback underpin a downside floor most growth names lack. The market is sleeping on the cash.
A maturing monopoly meeting real competition at ~41× forward earnings. Medtronic’s Hugo (FDA-cleared, Dec ’25) and J&J’s Ottava (de novo filed, Jan ’26) bring deep hospital relationships; China tenders increasingly favor local robots; growth is guided down to low-teens; tariffs press the margin. The multiple has nowhere to go but down.
Two decades of clinical data, an ~11,000-system installed base, surgeon-training lock-in, and high switching costs don’t fall to a single new entrant. Because the market is underpenetrated, Hugo and Ottava expand the category as much as they split it. Morningstar/GuruFocus peg fair value near $596; the moat is the data and the surgeon, not just the robot.
What the sell-side expects over the next year. Bars are sorted low to high and colored by rating; the dashed line is today’s $411 — note how nearly every target sits above it.
Sell-side 12-month targets — a selection of the ~24 firms covering ISRG; the full consensus is ≈ $575, about +40% above today, with a Buy/Strong-Buy skew (~22 of 24). The dashed line marks today’s $411: only the most cautious desks (Deutsche Bank cut to $366, an HSBC-type Hold) sit at or below the current price — the rest see meaningful upside. Confirmed targets: Deutsche Bank $366 (cut Jun 2), BofA $515 (cut Jun 12), Piper Sandler $580 Overweight, Bernstein $750 (high). Other firms, ratings, and targets are representative of the published range as of mid-June 2026.
Synthesized scenario midpoints (mid-year). Returns shown vs. today’s $411.06. These are illustrative frameworks, not predictions with certainty — five-year outcomes hinge on growth durability, margins, and how much of a premium multiple the market keeps paying.
Where the money actually goes. The bull and the bear theses both live in the gap between these four bars — the FCF inflection as the buildout rolls off is the crux.
Intuitive’s asset-light engine in one view: revenue compounds ~17–21%/yr to ~$10.1B (2025), and free cash flow (olive) nearly doubled to $2.5B in 2025 as the manufacturing buildout finished and capex (clay) rolled off — the heart of the bull’s “cash inflection” thesis, with consensus near $4B in 2026. The fourth bar is shown as cash & investments (slate), not debt, because ISRG carries effectively zero financial debt and a ~$9–11B net-cash war chest — the inverse of a leveraged story. The bear’s worry: competition forces capex (new platforms, fleet/financing, price) back up and stalls the FCF ramp. Figures illustrative; 2026E from consensus.
The price targets aren’t pulled from the air — each is an EPS estimate times an exit multiple. Here’s the earnings ladder the scenarios are built on.
Pro-forma (non-GAAP) diluted EPS — the figure analysts apply multiples to, and which ties to the ~41× forward P/E (Jun ’26). Gray = reported (2024 ~$6.50, 2025 ~$8.90); olive = estimates assuming growth decelerating from the mid-teens toward ~13% by 2031. The base case’s ~$18.5 of 2031 EPS at a ~34× exit multiple ≈ the $640 base-case 5-year target — this is the ladder underneath those prices. (GAAP EPS was $8.00 in 2025; GAAP runs above pro-forma because of large interest/investment income on the cash pile.) Estimates illustrative.
Q1 FY26, year-over-year — read these against a stock sitting near its 52-week low.
Every line is green — procedures +17%, revenue +23%, EBITDA +30%, earnings +38% — with the newer frontier lines (Ion, da Vinci 5 placements) compounding far faster off smaller bases (clay). Yet the stock trades near its 52-week low. That gap is the bull’s entire case in one chart: the business is fine; the multiple compressed. da Vinci 5 placements shown Q4’25 YoY; some frontier figures off small bases — illustrative.
The entire valuation argument compresses into one disagreement: is Intuitive a durable compounder worth a premium, or a maturing monopoly about to be re-rated as competition arrives?
Where each risk sits, not just how big it is. The hot upper-right corner — likely and high-impact — is the one that matters; for ISRG it’s the multiple itself, with the competitive threats one row down in “possible.”
The ~41× forward multiple normalizes toward the med-tech average as growth matures — the single largest source of downside even if the business executes.
Medtronic and J&J convert deep hospital relationships into system placements, pressuring ISRG’s pricing and slowing installed-base growth.
Worldwide procedure growth slips below the 13–15% guide, breaking the recurring-revenue compounding the whole thesis rests on.
Provincial tenders favor local robots and win-rates fall, capping the international growth that underpins the long-run revenue CAGR.
Tighter hospital capital budgets and cost-effectiveness scrutiny slow system purchases and elective-procedure volume.
A deep-pocketed tech entrant (OpenAI-style robotics) or a da Vinci 5 safety event reprices the category overnight — low odds, high consequence.
Recalls or heightened FDA attention on da Vinci / Ion dent the safety reputation that anchors switching costs.
Defending the lead (Dv5 updates, digital/AI, force feedback) raises operating spend and could pressure the margin trajectory.
Tariffs and higher component costs compress the ~66% gross margin management already guided lower.
Hover the dotted terms in the metrics, or scan the desk’s working definitions here.